Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis
Kakinoki et al.,
Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19..,
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.01.067 (date from earlier preprint)
Retrospective 55 patients in Japan treated a median of 3 days from symptom onset with casirivimab/imdevimab, and 53 control patients, showing lower risk of further treatment including oxygen or antivirals.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].
risk of further treatment including oxygen or antivirals, 57.6% lower, RR 0.42, p = 0.049, treatment 13 of 55 (23.6%), control 22 of 53 (41.5%), NNT 5.6, adjusted per study, odds ratio converted to relative risk, multivariable.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Kakinoki et al., 4 Nov 2021, retrospective, Japan, peer-reviewed, 16 authors, average treatment delay 3.0 days.
Abstract: Journal Pre-proof
Impact of Antibody Cocktail Therapy Combined with Casirivimab and
Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life
Setting: A Single Institute Analysis
Yasutaka Kakinoki , Kazuki Yamada , Yoko Tanino , Keiko Suzuki ,
Takaya Ichikawa , Naoki Suzuki , Go Asari , Ai Nakamura ,
Shin Kukita , Akito Uehara , Seisuke Saito , Shohei Kuroda ,
Hidemitsu Sakagami , Yuuki Nagashima , Kae Takahashi ,
Satoshi Suzuki
PII:
DOI:
Reference:
S1201-9712(22)00076-5
https://doi.org/10.1016/j.ijid.2022.01.067
IJID 5989
To appear in:
International Journal of Infectious Diseases
Received date:
Revised date:
Accepted date:
10 December 2021
18 January 2022
30 January 2022
Please cite this article as: Yasutaka Kakinoki , Kazuki Yamada , Yoko Tanino , Keiko Suzuki ,
Takaya Ichikawa ,
Naoki Suzuki ,
Go Asari ,
Ai Nakamura ,
Shin Kukita ,
Akito Uehara ,
Seisuke Saito , Shohei Kuroda , Hidemitsu Sakagami , Yuuki Nagashima , Kae Takahashi ,
Satoshi Suzuki , Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on
Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis, International
Journal of Infectious Diseases (2022), doi: https://doi.org/10.1016/j.ijid.2022.01.067
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
Highlights for review
Covid-19 patients with high-risk factors in a real-life practice were analyzed.
The cocktail combined with casirivimab and imdevimab was given consecutively.
The efficacy was compared with those patients without the cocktail.
The cocktail significantly reduced 70% in need of additional medical
intervention.
Impact of Antibody Cocktail Therapy Combined with Casirivimab
and Imdevimab on Clinical Outcome for Covid-19 patients in A
Real-Life Setting: A Single Institute Analysis
Yasutaka Kakinoki, MD, PhD1), Kazuki Yamada, MD 1),
Yoko Tanino, MD
1), Keiko Suzuki, MD 1), Takaya Ichikawa, MD 1), Naoki Suzuki, MD 2), Go
Asari, BA 2), Ai Nakamura, MD 1), Shin Kukita, MD 1), Akito Uehara, MD
1), Seisuke Saito, MD 1), Shohei Kuroda, MD 1), Hidemitsu Sakagami, MD
1), Yuuki Nagashima, MD 1), Kae Takahashi, MD 1), and Satoshi Suzuki,
MD 1)
1) Division of Internal Medicine, Asahikawa City Hospital, Asahikawa,
Japan
2) Asahikawa City Health Center, Asahikawa, Japan
Corresponding author:
Yasutaka Kakinoki, MD, PhD.
Asahikawa City Hospital, 1-1-65, Kinseicho, Asahikawa, 070-8610, Japan
e-mail: y_kakinoki@ach.hokkaido.jp
Keywords: Covid-19; SARS-CoV-2; cocktail; ronapreve; REGEN-COV
ABSTRACT
Background. Recent data from clinical trials suggest that antibody cocktail
therapy with casirivimab and imdevimab is linked to reduction of the risk of
hospitalization or death among high-risk patients with..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit